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Reversible Dysphasia and Statins
This paper presents a case of reversible dysphasia occurring in a patient prescribed 
atorvastatin in combination with indapamide. A milder dysphasia recurred with the 
prescription of rosuvastatin and was documented on clinical examination. This resolved 
following cessation of rosuvastatin. The case highlights both a need for a wider 
understanding of potential drug interactions through the CYP 450 system and for an 
increased awareness, questioning and reporting of drug side-effects.
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CASE REPORT
Neuroscience
INTRODUCTION
Statins are a very widely used class of medication and controlled 
studies have demonstrated clear benefits with respect to cardi-
ac disorders and also stroke and cognitive function. Because of 
this there are moves toward their use in primary prevention of 
atherosclerosis (1). However they are not without side effects. 
The literature includes numerous reports of cognitive dysfunc-
tion (2) even though their occurrence was not borne out as a 
general effect in the controlled trials (e.g.3). However the previ-
ously published reports have not mentioned aphasia or dys-
phasia as a specific side effect except as part of a much wider 
and more serious problem (4).
  Despite this a general search of the internet does provide sev-
eral allegations of language problems occurring with statin use. 
The evidence provided in association with these allegations is 
either absent or poor. However as at the 30th March 2011 the 
Australian register of drug adverse reactions records six cases of 
aphasic disturbance with atorvastatin, one with rosuvastatin 
and two with simvastatin (Goodwin, personal communication). 
These numbers include the presently reported case.
  This case is presented as a reasonably well documented oc-
currence of dysphasia associated with the use of atorvastatin 
and rosuvastatin and a consideration of some of the factors that 
might be involved in both the genesis of the syndrome and the 
absence of documented reports.
CASE DESCRIPTION
Mrs. X. Y. a 58-yr-old Caucasian woman, presented for medico-
legal examination on the 14th of April 2010 with regard to a com-
pensation claim involving allegations of harassment at work 
producing anxiety and depression. At the time of her initial pre-
sentation for treatment her general practitioner had noted that 
her blood pressure was higher than usual and had prescribed 
the statin Lipitor (atorvastatin) 10 mg per day together with in-
dapamide 2.5 mg per day.
  A few days later Mrs. X. Y. reported that she had developed 
problems in “word finding” in that her speech would be inter-
rupted because she would be unable to find a word to describe 
an object. Mrs. X. Y. had ceased the Lipitor after a few days and 
said that her symptoms had resolved quite quickly. She had seen 
her doctor four weeks later and the doctor had noted “Had symp-
toms of haziness and confusion with the Lipitor tablets so pa-
tient had stopped them. Nil symptoms since then. Claims it may 
have been due to her anxiety. Unlikely above symptoms due to 
Lipitor” At this point Mrs. X. Y. had been commenced on Crestor 
(rosuvastatin) 5 mg daily while continuing on indapamide.
  Four weeks later at her medico-legal assessment Mrs. X.Y. was 
noted to have clear but intermittent difficulty in word finding. 
She was also tense and tearful at times. She was a little perfec-
tionistic but there was no evidence of any psychotic symptoms. 
There were no gross neurological abnormalities.
  Mrs. X. Y. was reviewed two weeks later. At this point she had 
stopped the rosuvastatin and her speech was fluent and clear. 
Mrs. X. Y. was continuing to take indapamide 2.5 mg per day.
  A review of Mrs. X. Y.’s investigations indicated that a the time 
she had been prescribed Lipitor her total cholesterol was 6.1 
mM (HDL 1.27, LDL 3.77), trigycerides 2.34 mM and fasting 
glucose 5.8 mM. Electrolytes and liver function tests did not 
show any specific abnormality. An exercise ECG carried out 
two weeks after the prescription of atorvastatin was normal.
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Mrs. X. Y. had developed dysphasia as a direct side effect of the 
use of simvastatin. That this is likely to have been a generic statin 
effect is supported by the recurrence of milder symptoms on 
rosuvastatin and their remission on its cessation. Using the meth-
od of attribution recommended by Naranjo and colleagues (5) 
it would rate at 9 (definite adverse reaction).
  The greater effect resulting from the rosuvastatin is likely to 
reflect the co-incident prescription of indapamide as both drugs 
are metabolised through the CYP 450 3A4 pathway whereas ro-
suvastatin is metabolised via the CYP 450 2C9 pathway (6, 7).
  However a larger question is why speech should be selective-
ly affected. There is clear evidence that aphasia can be included 
in the syndrome of mitochondrial encephalopathy (MELAS) (8) 
but in this case there is no history of other mitochondrial dys-
function such as muscle weakness. Wagstaff and colleagues (2) 
suggest that inhibition of membrane synthesis may affect the 
neuronal membrane. This is supported by Baker and Tarnopol-
sky (9) who also suggest that decreased ubiquinone (Co-enzyme 
Q10) synthesis may lead to decreased ATP production and re-
duced free radical scavenging, and by Ihara and colleagues who 
report that the cerebral pathology occurring in their MELAS pa-
tients reflected damage at a cellular rather than vascular level (6). 
It may be that speech requires a selective increase in neuronal 
metabolism and is therefore a vulnerable function.
  A genetic vulnerability may also be hypothesised. This has 
already been studied in relation to statin induced myopathy (10). 
Slow CYP 450 metabolisers are likely to have proportionately 
higher blood levels and there may also be a genetically deter-
mined increased sensitivity to lower ubiquinone levels within 
the mitochondria in some patients (11).
  Given the history of the episodes in this patient and the com-
ments written in the attending practitioners notes it would seem 
that other episodes of similar syndromes may be more common 
than reported. I subsequently have had one further patient ret-
rospectively report transient cognitive symptoms on a statin. 
The patient had stopped the medication and did not advise their 
doctor. 
  Accad (12) notes that one of the problems in the use of statins 
is the immediacy of side effects and the long delay of benefits. 
However another problem would seem that there tends to be a 
“one size fits all” approach and that because of the substantial 
overall benefits of statin use significant side effects are masked 
in large trials. Some greater attention to the group reporting side 
effects may demonstrate significant markers such as CYP 450 
slow metabolising that would allow prediction of the at risk group 
as well as defining specific genetic abnormalities in cerebral lip-
id metabolism such as those reported by Hollingworth and col-
leagues (13). Also this particular case draws attention to a need 
for greater awareness of possible drug interactions through the 
CYP 450 system amongst primary care physicians.
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